Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

preladenant

- PMLiVE

Merck shares positive results for Keytruda in phase 3 kidney cancer study

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Michael J Fox Foundation awards Vesper Bio over $870,000 for Parkinson’s treatment

Vesper is currently developing VES001 for GRN-mutated frontotemporal dementia

- PMLiVE

New framework establishes two tests for use in clinical trials for Parkinson’s

The neurological condition currently affects around 145,000 people in the UK

- PMLiVE

Merck expands cancer immunotherapy pipeline with $680m Harpoon acquisition

The deal includes a T-cell engager for lung cancer and neuroendocrine tumours

- PMLiVE

Researchers develop new blood test to identify risk of Parkinson’s disease

The findings could help to identify people most likely to benefit from disease-modifying therapies

- PMLiVE

Study programme to investigate blocking brain inflammation in Parkinson’s patients

If successful, the findings could lead to new medicines to treat the neurological disease

- PMLiVE

AstraZeneca/Merck’s Lynparza recommended by NICE for advanced prostate cancer

The combination therapy has been recommended for patients regardless of biomarker status

- PMLiVE

Merck and Owkin collaborate to develop AI-powered diagnostics for cancer

The companies aim to develop a pre-screening test to improve MSI-H testing for cancer

- PMLiVE

Merck’s Keytruda approved by EC for two new gastrointestinal cancer indications

Both approvals follow recommendations from the European Medicines Agency’s human medicines committee

- PMLiVE

Newel Health launches study of digital therapeutic for Parkinson’s disease

The Soturi app is designed to optimise personalised treatment plans for patients

- PMLiVE

Merck shares positive phase 3 results for investigational pneumococcal vaccine in adults

V116 is designed to address the strains responsible for adult pneumococcal disease

- PMLiVE

Merck’s Keytruda combination receives CHMP recommendation for biliary tract cancer

Approximately 211,000 people are diagnosed with the disease globally each year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links